Regeneron Pharmaceuticals (REGN -0.7%) announces that the FDA has approved Eylea Injection for the treatment of macular edema. The approval was based on data from Phase 3 studies which showed results for Eylea were superior to those for the sham control group for the primary endpoint.
Sent to 6,868 people who get email alerts on REGN.
Get email alerts on REGN »
Want to be faster and smarter on all your stocks?
Upgrade all your basic real-time alerts to PRO Alerts, for $30.